TABLE 5.
Variable | Na | Ratio (95% CI) | z Test, P | TOST | |
---|---|---|---|---|---|
z1 P | z2 P | ||||
PPVb | .001 | .94 | <.001 | ||
M-CHAT | 98 | 0.57 (0.47–0.67) | |||
PCP M-CHAT/F | 98 | 0.78 (0.69–0.86) | |||
PPVc | .30 | .29 | .004 | ||
PCP M-CHAT/F | 98 | 0.78 (0.69–0.86) | |||
AC M-CHAT/F | 97 | 0.71 (0.62–0.80) | |||
Sensitivityc | .38 | 0.30 | .01 | ||
PCP M-CHAT/F | 98 | 0.55 (0.46–0.65) | |||
AC M-CHAT/F | 97 | 0.49 (0.39–0.59) | |||
Specificityc | .43 | .20 | .008 | ||
PCP M-CHAT/F | 98 | 0.79 (0.70–0.87) | |||
AC M-CHAT/F | 97 | 0.74 (0.65–0.83) | |||
Accuracyc | .24 | .40 | .005 | ||
PCP M-CHAT/F | 98 | 0.60 (0.56–0.75) | |||
AC M-CHAT/F | 97 | 0.57 (0.47–0.67) |
Table includes suspected ASD/new phenotype. Comparisons were made with 2-tailed z test and TOST, Δ = 0.1 unit of proportion. Only patients with a positive screen on the M-CHAT are included in this sample. CI, confidence interval.
One patient did not have a complete AC M-CHAT/F (Fig 1).
Relevant difference.
Equivalence.